

浏览全部资源
扫码关注微信
山西中医药大学,山西省晋中市榆次区大学街121号,030600
Received:11 January 2024,
Revised:2024-05-15,
Published:02 August 2024
移动端阅览
武东燕,桂婉威,王小丹等.地黄饮子对阿尔茨海默病模型小鼠视网膜胰岛素含量及胰岛素信号通路相关蛋白表达的影响[J].中医杂志,2024,65(15):1593-1601.
WU Dongyan,GUI Wanwei,WANG Xiaodan,et al.Effect of Dihuang Yinzi Decoction (地黄饮子)on Retinal Insulin Content and Insulin Signaling Pathway Related Protein Expression in Alzheimer's Disease Model Mice[J].Journal of Traditional Chinese Medicine,2024,65(15):1593-1601.
武东燕,桂婉威,王小丹等.地黄饮子对阿尔茨海默病模型小鼠视网膜胰岛素含量及胰岛素信号通路相关蛋白表达的影响[J].中医杂志,2024,65(15):1593-1601. DOI: 10.13288/j.11-2166/r.2024.15.012.
WU Dongyan,GUI Wanwei,WANG Xiaodan,et al.Effect of Dihuang Yinzi Decoction (地黄饮子)on Retinal Insulin Content and Insulin Signaling Pathway Related Protein Expression in Alzheimer's Disease Model Mice[J].Journal of Traditional Chinese Medicine,2024,65(15):1593-1601. DOI: 10.13288/j.11-2166/r.2024.15.012.
目的
2
以视网膜为窗口观察地黄饮子改善阿尔茨海默病(AD)认知功能障碍的可能作用机制。
方法
2
45只APP/PS1小鼠(AD模型小鼠)随机分为模型组、地黄饮子组、美金刚组,每组15只;15只同窝野生型C57BL/6J小鼠作为空白组。地黄饮子组小鼠予地黄饮子30.03 g/(kg·d)灌胃,美金刚组小鼠予盐酸美金刚6.1 mg/(kg·d)灌胃,空白组和模型组小鼠予生理盐水2 ml/(kg·d)灌胃,连续干预4周。每周检测小鼠空腹血糖。干预4周后进行口服糖耐量试验(OGTT)、胰岛素耐量试验(ITT);采用莫里斯水迷宫检测小鼠空间记忆能力的变化;葡萄糖氧化酶法检测小鼠视网膜葡萄糖含量;酶联免疫吸附测定(ELISA)检测小鼠血清、视网膜胰岛素含量,计算胰岛素抵抗指数(HOMA-IR)。苏木素-伊红(HE)染色观察视网膜组织病理改变,并统计视网膜厚度和神经节细胞数;蛋白免疫印迹法检测视网膜通路相关蛋白[胰岛素受体底物1(IRS1)、磷酸化胰岛素受体底物1(pIRS1)、磷脂酰肌醇-3-羟激酶(PI3K)、蛋白激酶B(Akt1)、磷酸化蛋白激酶B(pAkt1)]表达量;免疫组化法检测视网膜葡萄糖转运蛋白4(GLUT4)表达。
结果
2
与空白组相比,模型组1、2、3、4周时小鼠空腹血糖,OGTT和ITT试验各时间点血糖及曲线下面积,空腹血清胰岛素和HOMA-IR均升高(
P
<0.05或
P
<0.01);莫里斯水迷宫实验中第3~5天逃避潜伏期增加,穿越平台次数、目标象限运动距离占总距离的比例、目标象限运动时间占总时间的比例均减少(
P
<0.05或
P
<0.01);视网膜外核层细胞排列稀疏,厚度变薄,神经节细胞数量减少(
P
<0.01);视网膜葡萄糖表达量升高,胰岛素含量、pIRS1/IRS1、PI3K/β-Actin、pAkt1/Akt1、GLUT4蛋白表达量降低(
P
<0.01)。与模型组相比,地黄饮子组小鼠4周时空腹血糖、OGTT和ITT试验各时间点血糖及曲线下面积降低(
P
<0.05或
P
<0.01),空腹血清胰岛素和HOMA-IR降低(
P
<0.05);莫里斯水迷宫试验中第4、5天逃避潜伏期缩短、穿越平台次数、目标象限距离占总距离的比例、目标象限运动时间占总时间的比例减少(
P
<0.05或
P
<0.01);视网膜病理改变减轻,视网膜厚度和神经节细胞数量增加(
P
<0.01);视网膜葡萄糖含量降低,视网膜pIRS1/IR
S1、PI3K/β-Actin、GLUT4蛋白表达量升高(
P
<0.05或
P
<0.01)。
结论
2
地黄饮子可以改善AD认知功能障碍,可能与调节视网膜胰岛素含量及胰岛素信号通路有关。
Objective
2
To observe the possible mechanism of
Dihuang Yinzi Decoction
(地黄饮子) for improving cognitive dysfunction in Alzheimer's disease (AD) from the perspective of retina.
Methods
2
Forty-five APP/PS1 mice (AD model mice) were randomly divided into model group,
Dihuang Yinzi Decoction
group, and memantine group, with 15 mice in each group, while 15 wild-type C57BL/6J mice from the same litter were used as blank group. Mice in
Dihuang Yinzi Decoction
group were given
Dihuang Yinzi Decoction
30.03 g/(kg·d) by gavage, mice in the memantine group were given memantine hydrochloride 6.1 mg/(kg·d) by gavage, and mice in the blank group and the model group were given normal saline 2 ml/(kg·d) by gavage for 4 consecutive weeks. Fasting blood glucose was measured weekly. After 4 weeks of intervention, oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) were performed; Morris water maze was used to detect the changes in spatial memory ability of mice; glucose oxidase method was used to detect retinal glucose content of mice; enzyme-linked immunosorbent assay (ELISA) was used to detect serum and retinal insulin content of mice, and Homeostatic Model Assessment of insulin resistance (HOMA-IR) was calculated. Hematoxylin-eosin (HE) staining was performed to observe the histopathological changes in the retina, and the retinal thickness and ganglion cell number were counted; protein immunoblotting was performed to detect the retinal pathway-associated proteins [insulin receptor substrate 1 (IRS1), phosphorylated insulin receptor substrate 1 (pIRS1), phosphatidylinositol-3-hydroxykinase (PI3K), protein kinase B (Akt1), phosphorylated protein kinase B (pAkt1)] expressi
on; retinal glucose transporter protein 4 (GLUT4) expression was detected by immunohistochemistry.
Results
2
Compared with the blank group, fasting blood glucose of mice in the model group at weeks 1, 2, 3, and 4, blood glucose and area under the curve (AUC) at different time point of OGTT and ITT test, fasting serum insulin, and HOMA-IR increased (
P
<0.05,
P
<0.01); in the Morris water maze experiment, the escape latency increased from day 3 to day 5, and the number of crossing platforms, the percentage of target quadrant distance, and the percentage of target quadrant time decreased (
P
<0.05,
P
<0.01); the outer nuclear layer of the retina became sparse, thinner, and the number of ganglion cells decreases (
P
<0.01); the expression level of retinal glucose increased, while the expression levels of insulin, pIRS1/IRS1, PI3K/β-Actin, pAkt1/Akt1, and GLUT4 proteins decreased (
P
<0.01). Compared with the model group, fasting blood glucose at week 4, blood glucose at each time point of the OGTT and ITT tests AUC decreased (
P
<0.05,
P
<0.01), and fasting serum insulin and HOMA-IR decreased (
P
<0.05) in
Dihuang Yinzi Decoction
group; In the Morris water maze test, the escape latency shortened on day 4 and day 5, number of platform crossings, target quadrant distance as a proportion of total distance, and target quadrant movement time as a proportion of total time decreased (
P
<0.05,
P
<0.01); retinal pathological changes alleviated, and retinal thickness and ganglion cell number increased (
P
<0.01); retinal glucose content decreased, and retinal pIRS1/IRS1, PI3K/β-Actin, and GLUT4 protein expression elevated (
P
<0.05 or
P
<0.01).
Conclusions
2
Dihuang Yinzi Decoction
can improve cognitive dysfunction of Alzhe
imer's disease, which may be related to regulating retinal insulin content and insulin signaling pathway.
KELLAR D , CRAFT S . Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches [J]. Lancet Neurol , 2020 , 19 ( 9 ): 758 - 766 .
ARNOLD SE , ARVANITAKIS Z , MACAULEY-RAMBACH SL , et al . Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums [J]. Nat Rev Neurol , 2018 , 14 ( 3 ): 168 - 181 .
SHARMA VK , SINGH TG . Insulin resistance and bioenergetic manifestations: targets and approaches in Alzheimer's disease [J]. Life Sci , 2020 , 262 : 118401 . doi: 10.1016/j.lfs.2020.118401 http://dx.doi.org/10.1016/j.lfs.2020.118401 .
KORONYO Y , RENTSENDORJ A , MIRZAEI N , et al . Retinal pathological features and proteome signatures of Alzheimer's disease [J]. Acta Neuropathol , 2023 , 145 ( 4 ): 409 - 438 .
MAJEED A , MARWICK B , YU H , et al . Ophthalmic biomarkers for Alzheimer's disease: a review [J]. Front Aging Neurosci , 2021 , 13 : 720167 . doi: 10.3389/fnagi. 2021.720167 http://dx.doi.org/10.3389/fnagi.2021.720167 .
帅月圆 , 韩诚 , 曹建华 , 等 . 基于 1 H-NMR血清代谢组学的阿尔茨海默病肾虚精亏证生物学机制及地黄饮子的干预作用研究 [J]. 山西中医药大学学报 , 2021 , 22 ( 4 ): 252 - 257,263 .
ZHANG Z , ZHU Y , ZHU C , et al . Effects of Dihuang Yinzi decoction on Alzheimer's disease: a systematic review and meta-analysis [J]. Complement Med Res , 2023 , 30 ( 5 ): 440 - 452 .
KLAKOTSKAIA D , AGCA C , RICHARDSON RA , et al . Memory deficiency, cerebral amyloid angiopathy, and amyloid-β plaques in APP+PS1 double transgenic rat model of Alzheimer's disease [J]. PLoS One , 2018 , 13 ( 4 ): e0195469 .
陈奇 . 中药药理研究方法学 [M]. 北京 : 人民卫生出版社 , 2006 : 28 .
ARVANITAKIS Z , SHAH RC , BENNETT DA . Diagnosis and management of dementia: review [J]. JAMA , 2019 , 322 ( 16 ): 1589 - 1599 .
PAN Y , CHEN W , YAN H , et al . Glycemic traits and Alzheimer's disease: a mendelian randomization study [J]. Aging (Albany NY) , 2020 , 12 ( 22 ): 22688 - 22699 .
ZHOU Y , DONG J , SONG J , et al . Efficacy of glucose metabolism-related indexes on the risk and severity of Alzheimer's disease: a meta-analysis [J]. J Alzheimers Dis , 2023 , 93 ( 4 ): 1291 - 1306 .
LI XY , MEN WW , ZHU H , et al . Age- and brain region-specific changes of glucose metabolic disorder, learning, and memory dysfunction in early Alzheimer's disease assessed in APP/PS1 transgenic mice using 18F-FDG-PET [J]. Int J Mol Sci , 2016 , 17 ( 10 ): 1707 .
MACKLIN L , GRIFFITH CM , CAI Y , et al . Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline [J]. Exp Gerontol , 2017 , 88 : 9 - 18 . doi: 10.1016/j.exger.2016.12.019 http://dx.doi.org/10.1016/j.exger.2016.12.019 .
SZEGEDI S , DAL-BIANCO P , STÖGMANN E , et al . Anatomical and functional changes in the retina in patients with Alzheimer's disease and mild cognitive impairment [J]. Acta Ophthalmol , 2020 , 98 ( 7 ): e914 - e921 .
COSTANZO E , LENGYEL I , PARRAVANO M , et al . Ocular biomarkers for Alzheimer disease dementia: an umbrella review of systematic reviews and meta-analyses [J]. JAMA Ophthalmol , 2023 , 141 ( 1 ): 84 - 91 .
CECILIA SL , ERIC BL , LAURA EG , et al . Ophthalmology-based neuropathology risk factors: diabetic retino-pathy is associated with deep microinfarcts in a community-based autopsy study [J]. J Alzheimer's Dis , 2019 , 68 ( 2 ): 647 - 655 .
KASHANI AH , ASANAD S , CHAN JW , et al . Past, present and future role of retinal imaging in neurodegenerative disease [J]. Prog Retin Eye Res , 2021 , 83 : 100938 . doi: 10.1016/j.preteyeres.2020.100938 http://dx.doi.org/10.1016/j.preteyeres.2020.100938 .
LE TKC , DAO XD , NGUYEN DV , et al . Insulin signaling and its application [J]. Front Endocrinol (Lausanne) , 2023 , 14 : 1226655 . doi: 10.3389/fendo.2023.1226655 http://dx.doi.org/10.3389/fendo.2023.1226655 .
LETO D , SALTIEL AR . Regulation of glucose transport by insulin: traffic control of GLUT4 [J]. Nat Rev Mol Cell Biol , 2012 , 13 ( 6 ): 383 - 396 .
SEN S , SAXENA R , TRIPATHI M , et al . Neurodege-neration in Alzheimer's disease and glaucoma: overlaps and missing links [J]. Eye (Lond) , 2020 , 34 ( 9 ): 1546 - 1553 .
LITTLE K , LLORIÁN-SALVADOR M , SCULLION S , et al . Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline [J]. Trends Endocrinol Metab , 2022 , 33 ( 1 ): 50 - 71 .
FAIQ MA , SENGUPTA T , NATH M , et al . Ocular ma-nifestations of central insulin resistance [J]. Neural Regen Res , 2023 , 18 ( 5 ): 1139 - 1146 .
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010102007558号